Clinical Trials Directory

Trials / Sponsors / Allarity Therapeutics

Allarity Therapeutics

Industry · 8 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
SuspendedStudy to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Co
Advanced Solid Tumors
Phase 12023-02-20
TerminatedAnti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Metastatic Breast Cancer
Phase 22021-03-01
RecruitingInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Advanced Ovarian Cancer
Phase 22019-04-15
RecruitingClinical Pre-screening Protocol for Ovarian Cancer
Ovarian Cancer
—2019-04-11
CompletedIrofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Metastatic Castration-Resistant Prostate Cancer Patients
Phase 22018-10-17
CompletedInvestigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic
Metastatic Breast Cancer
Phase 22018-06-20
TerminatedSafety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selecte
Relapsed/Refractory Multiple Myeloma
Phase 1 / Phase 22017-06-13
CompletedPhase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory T
Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Phase 1 / Phase 22013-04-01